Quality of life, delinquency and psychosocial functioning of adolescents in secure residential care: testing two assumptions of the Good Lives Model

Autor: C. S. Barendregt, A. M. Van der Laan, I. L. Bongers, Ch. Van Nieuwenhuizen

Publikováno v: Child and Adolescent Psychiatry and Mental Health, Vol 12, Iss 1, Pp 1-10 (2018)

Abstract Background In this study, two assumptions derived from the Good Lives Model were examined: whether subjective Quality of Life is related to delinquent behaviour and psychosocial problems, and whether adolescents with adequate coping skills a

Externí odkaz: https://doaj.org/article/c877c2747fd64d739ba92ac1d0116d1c

J. Exalto, Gereformeerde heiligen. De religieuze exempeltraditie in vroegmodern Nederland

Autor: Ch. van Leeuwen

Publikováno v: BMGN: Low Countries Historical Review, Vol 121, Iss 3, Pp 505-507 (2006)

Externí odkaz: https://doaj.org/article/7a685563a4814476b7b16135ee14251f

Safe shortening of antibiotic treatment duration for complicated Staphylococcus aureus bacteraemia (SAFE trial): protocol for a randomised, controlled, open-label, non-inferiority trial comparing 4 and 6 weeks of antibiotic treatment

Autor: N Roescher, JM Prins, JTM van der Meer, HI Bax, R Soetekouw, MGJ de Boer, LBS Gelinck, JJ Oosterheert, MA van Agtmael, M Berrevoets, DTP Buis, CH van Werkhoven, MJM Bonten, JE Bosmans, J Branger, S Douiyeb, E Jong, AJJ Lammers, E Sieswerda, JE Stalenhoef, TW Van der Vaart, EA Bij de Vaate, NJ Verkaik, MGA Van Vonderen, PJ De Vries, KCE Sigaloff, E Botman, A Van den Broek, L Buitenhuis, E Buitenwerf, A S Cents, N Engels, J L J Hanssen, A J Meinders, F P N Mollema, L Nagelmaker, M L M van Doorn-Schepens, P Thomopoulos, M Timmer, B van der Wiel

Publikováno v: BMJ Open, Vol 13, Iss 4 (2023)

Introduction A major knowledge gap in the treatment of complicated Staphylococcus aureus bacteraemia (SAB) is the optimal duration of antibiotic therapy. Safe shortening of antibiotic therapy has the potential to reduce adverse drug events, length of

Externí odkaz: https://doaj.org/article/cf2fa20a75a4412a9dbd8b21a6ce2c68

Human monoclonal antibodies against Staphylococcus aureus surface antigens recognize in vitro and in vivo biofilm

Autor: Lisanne de Vor, Bruce van Dijk, Kok van Kessel, Jeffrey S Kavanaugh, Carla de Haas, Piet C Aerts, Marco C Viveen, Edwin C Boel, Ad C Fluit, Jakub M Kwiecinski, Gerard C Krijger, Ruud M Ramakers, Freek J Beekman, Ekaterina Dadachova, Marnix GEH Lam, H Charles Vogely, Bart CH van der Wal, Jos AG van Strijp, Alexander R Horswill, Harrie Weinans, Suzan HM Rooijakkers

Publikováno v: eLife, Vol 11 (2022)

Implant-associated Staphylococcus aureus infections are difficult to treat because of biofilm formation. Bacteria in a biofilm are often insensitive to antibiotics and host immunity. Monoclonal antibodies (mAbs) could provide an alternative approach

Externí odkaz: https://doaj.org/article/f9dfe179409a4ffabf19a218bc324d32

Safe shortening of antibiotic treatment duration for complicated Staphylococcus aureus bacteraemia (SAFE trial): protocol for a randomised, controlled, open-label, non-inferiority trial comparing 4 and 6 weeks of antibiotic treatment

Autor: DTP Buis, CH van Werkhoven, MA van Agtmael, HI Bax, M Berrevoets, MGJ de Boer, MJM Bonten, JE Bosmans, J Branger, S Douiyeb, LBS Gelinck, E Jong, AJJ Lammers, JTM Van der Meer, JJ Oosterheert, E Sieswerda, R Soetekouw, JE Stalenhoef, TW Van der Vaart, EA Bij de Vaate, NJ Verkaik, MGA Van Vonderen, PJ De Vries, JM Prins, KCE Sigaloff

Publikováno v: BMJ open, 13(4):e068295. BMJ Publishing Group
BMJ Open, 13(4):e068295, 1-26. BMJ Publishing Group
Collaborators SAFE-trial study group 2023, ' Safe shortening of antibiotic treatment duration for complicated Staphylococcus aureus bacteraemia (SAFE trial) : protocol for a randomised, controlled, open-label, non-inferiority trial comparing 4 and 6 weeks of antibiotic treatment ', BMJ Open, vol. 13, no. 4, e068295, pp. e068295 . https://doi.org/10.1136/bmjopen-2022-068295
BMJ Open, 13(4). BMJ Publishing Group
BMJ Open, 13(4):e068295. BMJ Publishing Group
Buis, D T P, Van Werkhoven, C H, Van Agtmael, M A, Bax, H I, Berrevoets, M, De Boer, M G J, Bonten, M J M, Bosmans, J E, Branger, J, Douiyeb, S, Gelinck, L B S, Jong, E, Lammers, A J J, Van Der Meer, J T M, Oosterheert, J J, Sieswerda, E, Soetekouw, R, Stalenhoef, J E, Van Der Vaart, T W, Bij De Vaate, E A, Verkaik, N J, Van Vonderen, M G A, De Vries, P J, Prins, J M & Sigaloff, K C E 2023, ' Safe shortening of antibiotic treatment duration for complicated Staphylococcus aureus bacteraemia (SAFE trial) : Protocol for a randomised, controlled, open-label, non-inferiority trial comparing 4 and 6 weeks of antibiotic treatment ', BMJ Open, vol. 13, no. 4, e068295, pp. 1-26 . https://doi.org/10.1136/bmjopen-2022-068295

IntroductionA major knowledge gap in the treatment of complicatedStaphylococcus aureusbacteraemia (SAB) is the optimal duration of antibiotic therapy. Safe shortening of antibiotic therapy has the potential to reduce adverse drug events, length of ho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af21151bb8a9b51016d71c3255ece501
https://pure.amc.nl/en/publications/safe-shortening-of-antibiotic-treatment-duration-for-complicated-staphylococcus-aureus-bacteraemia-safe-trial(7669693a-f906-448b-b63f-7135141cbf37).html